Recent Updates
Recently added Catalysts
TLSA

Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 3 June 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotec

Key Takeaway: Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 3 June 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for in

Full Press Release Details

Tiziana Life Sciences plc
(Incorporated in England and
Wales with company number 09665181)
New York/London, 3 June 2019 -
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative
therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners Limited, an entity
closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of
the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City
Code on Takeovers and Mergers.
The information set out below is provided
in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:
1. Details of PDMR / person closely associated
a) Name Gabriele Cerrone/Panetta Partners Limited
2. Reason for the notification: On market acquisition
a) Position / status Executive Chairman
b) Initial notification /amendment Initial notification
3. Details of the issuer
a) Name Tiziana Life Sciences plc
b) LEI 213800CED47HI8PIOB36
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of nominal value 3p each
b) Identification code of the Financial Instrument GB00BKWNZY55
c) Nature of the transaction On market acquisition of ordinary shares
d) Price(s) and volume(s) Price: 0.5700; Volume: 5,000 Price: 0.5865; Volume: 6,000
e) Aggregated information - Aggregated volume - Price 11,000 6,369
f) Date of the transaction 31 May 2019
g) Place of the transaction XLON
As a result of this transaction Mr Cerrone's
interests in the underlying ordinary shares of the Company increases from 64,214,425 (47.056%) to 64,225,425 (47.064%). Mr Cerrone's
interests in the ordinary shares of the Company are based on a holding of 63,680,404 ordinary shares held by Planwise Limited and
voting rights in respect of 545,021 ordinary shares held by Panetta Partners Limited (as shares and via ADSs). Mr Cerrone is considered
beneficially interested in the holdings of Panetta Partners Limited and Planwise Limited.
For more information go to http://www.tizianalifesciences.com
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner +44 (0)20 7213 0883
Stockdale Securities (Broker) Antonio Bossi / Andy Crossley +44 (0)20 7601 6100
Last updated: Jun 3, 2019